{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:32:04Z","timestamp":1791243124875,"version":"4.1.0"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 DK076007"],"award-info":[{"award-number":["R01 DK076007"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AR059357"],"award-info":[{"award-number":["R01-AR059357"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10-RR023710"],"award-info":[{"award-number":["S10-RR023710"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-AR065971"],"award-info":[{"award-number":["T32-AR065971"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Veteran's Administration","award":["BX002104-01"],"award-info":[{"award-number":["BX002104-01"]}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.bone.2016.10.007","type":"journal-article","created":{"date-parts":[[2016,10,15]],"date-time":"2016-10-15T22:23:54Z","timestamp":1476570234000},"page":"29-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":420,"special_numbering":"C","title":["Role and mechanism of action of sclerostin in bone"],"prefix":"10.1016","volume":"96","author":[{"given":"Jesus","family":"Delgado-Calle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Y.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresita","family":"Bellido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2016.10.007_bb0010","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/bonekey.2015.36","article-title":"A new WNT on the bone: WNT16, cortical bone thickness, porosity and fractures","volume":"4","author":"Gori","year":"2015","journal-title":"Bonekey Rep."},{"issue":"13","key":"10.1016\/j.bone.2016.10.007_bb0015","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J."},{"issue":"20","key":"10.1016\/j.bone.2016.10.007_bb0020","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"22","key":"10.1016\/j.bone.2016.10.007_bb0025","doi-asserted-by":"crossref","first-page":"19489","DOI":"10.1074\/jbc.M110.190330","article-title":"Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function","volume":"286","author":"Leupin","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bone.2016.10.007_bb0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00439-011-0947-3","article-title":"Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia","volume":"129","author":"Kim","year":"2011","journal-title":"Hum. Genet."},{"issue":"5","key":"10.1016\/j.bone.2016.10.007_bb0035","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.bone.2016.10.007_bb0040","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J. Bone Miner. Res."},{"issue":"48","key":"10.1016\/j.bone.2016.10.007_bb0045","doi-asserted-by":"crossref","first-page":"E5187","DOI":"10.1073\/pnas.1413828111","article-title":"Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels","volume":"111","author":"Chang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.bone.2016.10.007_bb0050","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3803\/EnM.2015.30.4.429","article-title":"Emerging therapies for osteoporosis","volume":"30","author":"McClung","year":"2015","journal-title":"Endocrinol. Metab. (Seoul)"},{"issue":"1","key":"10.1016\/j.bone.2016.10.007_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2011.10.025","article-title":"Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading","volume":"50","author":"Tu","year":"2012","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2016.10.007_bb0060","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/jbmr.304","article-title":"PTH receptor signaling in osteocytes governs periosteal bone formation and intra-cortical remodeling","volume":"26","author":"Rhee","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2016.10.007_bb0065","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/jbmr.2514","article-title":"High bone mass-causing mutant LRP5 receptors are resistant to endogenous inhibitors in vivo","volume":"30","author":"Niziolek","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0070","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1359\/jbmr.090730","article-title":"Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice","volume":"25","author":"Kramer","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.10.007_bb0075","article-title":"Osteocytic signalling pathways as therapeutic targets for bone fragility","author":"Plotkin","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"10.1016\/j.bone.2016.10.007_bb0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00223-011-9522-0","article-title":"Osteocyte deficiency in hip fractures","volume":"89","author":"Delgado-Calle","year":"2011","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bone.2016.10.007_bb0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1749-6632.2009.05246.x","article-title":"Dynamics of the transition from osteoblast to osteocyte","volume":"1192","author":"Dallas","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.bone.2016.10.007_bb0090","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1369\/jhc.2008.950527","article-title":"Matrix mineralization as a trigger for osteocyte maturation","volume":"56","author":"Irie","year":"2008","journal-title":"J. Histochem. Cytochem."},{"issue":"9","key":"10.1016\/j.bone.2016.10.007_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138189","article-title":"Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone","volume":"10","author":"Xiong","year":"2015","journal-title":"PLoS One"},{"issue":"52","key":"10.1016\/j.bone.2016.10.007_bb0100","doi-asserted-by":"crossref","first-page":"20764","DOI":"10.1073\/pnas.0805133106","article-title":"Regulation of bone formation by osteoclasts involves Wnt\/BMP signaling and the chemokine sphingosine-1-phosphate","volume":"105","author":"Pederson","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.bone.2016.10.007_bb0105","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/jcb.24537","article-title":"Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization","volume":"114","author":"Ota","year":"2013","journal-title":"J. Cell. Biochem."},{"issue":"6","key":"10.1016\/j.bone.2016.10.007_bb0110","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of sclerostin expression in multiple myeloma by Dkk-1; a potential therapeutic strategy for myeloma bone disease","volume":"31","author":"Eda","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1600-0765.2009.01227.x","article-title":"Localization of SOST\/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro","volume":"45","author":"Jager","year":"2010","journal-title":"J. Periodontal Res."},{"issue":"6","key":"10.1016\/j.bone.2016.10.007_bb0120","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0022034509338340","article-title":"Sclerostin in mineralized matrices and van Buchem disease","volume":"88","author":"Van Bezooijen","year":"2009","journal-title":"J. Dent. Res."},{"issue":"3","key":"10.1016\/j.bone.2016.10.007_bb0125","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.37802","article-title":"Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury","volume":"65","author":"Roudier","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2016.10.007_bb0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1471-2369-14-219","article-title":"Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study","volume":"14","author":"Brandenburg","year":"2013","journal-title":"BMC Nephrol."},{"issue":"5","key":"10.1016\/j.bone.2016.10.007_bb0135","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1172\/JCI24140","article-title":"Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals","volume":"115","author":"Shao","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bone.2016.10.007_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019595","article-title":"The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells","volume":"6","author":"Zhu","year":"2011","journal-title":"PLoS One"},{"issue":"330","key":"10.1016\/j.bone.2016.10.007_bb0145","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/scitranslmed.aac4351","article-title":"Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction","volume":"8","author":"Wehmeyer","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.bone.2016.10.007_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2011.22","article-title":"Myeloma cells suppress osteoblasts through sclerostin secretion","volume":"1","author":"Colucci","year":"2011","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bone.2016.10.007_bb0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1749-6632.2011.06196.x","article-title":"Sclerostin is overexpressed by plasma cells from multiple myeloma patients","volume":"1237","author":"Brunetti","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.bone.2016.10.007_bb0160","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/302416","article-title":"Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21","volume":"64","author":"Balemans","year":"1999","journal-title":"Am. J. Hum. Genet."},{"issue":"7","key":"10.1016\/j.bone.2016.10.007_bb0165","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1101\/gr.3437105","article-title":"Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease","volume":"15","author":"Loots","year":"2005","journal-title":"Genome Res."},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.10401","article-title":"A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population","volume":"110","author":"Staehling-Hampton","year":"2002","journal-title":"Am. J. Med. Genet."},{"issue":"12","key":"10.1016\/j.bone.2016.10.007_bb0175","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1359\/jbmr.070804","article-title":"Control of the SOST bone enhancer by PTH using MEF2 transcription factors","volume":"22","author":"Leupin","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"35","key":"10.1016\/j.bone.2016.10.007_bb0180","doi-asserted-by":"crossref","first-page":"14092","DOI":"10.1073\/pnas.1207188109","article-title":"Targeted deletion of Sost distal enhancer increases bone formation and bone mass","volume":"109","author":"Collette","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.bone.2016.10.007_bb0185","first-page":"698","article-title":"The role of DNA methylation in common skeletal disorders","volume":"1","author":"Delgado-Calle","year":"2012","journal-title":"Biology (Basel)"},{"issue":"4","key":"10.1016\/j.bone.2016.10.007_bb0190","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/jbmr.1491","article-title":"DNA methylation contributes to the regulation of sclerostin expression in human osteocytes","volume":"27","author":"Delgado-Calle","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2016.10.007_bb0195","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1210\/en.2011-1128","article-title":"Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin: a bone formation inhibitor","volume":"152","author":"Cohen-Kfir","year":"2011","journal-title":"Endocrinology"},{"issue":"36","key":"10.1016\/j.bone.2016.10.007_bb0200","doi-asserted-by":"crossref","first-page":"24995","DOI":"10.1074\/jbc.M114.564997","article-title":"Class I and IIa histone deacetylases have opposite effects on sclerostin gene regulation","volume":"289","author":"Baertschi","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.bone.2016.10.007_bb0205","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of PTH in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0210","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bone.2012.09.016","article-title":"Effects of PTH on osteocyte function","volume":"54","author":"Bellido","year":"2013","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0215","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"37","author":"Keller","year":"2005","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2016.10.007_bb0220","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.bone.2011.11.016","article-title":"TGF-beta regulates sclerostin expression via the ECR5 enhancer","volume":"50","author":"Loots","year":"2012","journal-title":"Bone"},{"issue":"22","key":"10.1016\/j.bone.2016.10.007_bb0225","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1242\/dev.025825","article-title":"BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway","volume":"135","author":"Kamiya","year":"2008","journal-title":"Development"},{"issue":"1\u20132","key":"10.1016\/j.bone.2016.10.007_bb0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2013.02.002","article-title":"Role of BMPs in the regulation of sclerostin as revealed by an epigenetic modifier of human bone cells","volume":"369","author":"Delgado-Calle","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"issue":"4","key":"10.1016\/j.bone.2016.10.007_bb0235","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbrc.2010.08.128","article-title":"Sclerostin is a direct target of osteoblast-specific transcription factor osterix","volume":"400","author":"Yang","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bone.2016.10.007_bb0240","first-page":"87","article-title":"Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts","volume":"110","author":"Genetos","year":"2010","journal-title":"J. Cell. Biochem."},{"issue":"15","key":"10.1016\/j.bone.2016.10.007_bb0245","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.febslet.2011.06.019","article-title":"Sost down-regulation by mechanical strain in human osteoblastic cells involves PGE2 signaling via EP4","volume":"585","author":"Galea","year":"2011","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.bone.2016.10.007_bb0250","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00223-013-9821-8","article-title":"Nitric oxide is involved in the down-regulation of SOST expression induced by mechanical loading","volume":"94","author":"Delgado-Calle","year":"2014","journal-title":"Calcif. Tissue Int."},{"issue":"51","key":"10.1016\/j.bone.2016.10.007_bb0255","doi-asserted-by":"crossref","first-page":"35939","DOI":"10.1074\/jbc.M109.060335","article-title":"The matricellular protein periostin is required for sclerostin inhibition and the anabolic response to mechanical loading and physical activity","volume":"284","author":"Bonnet","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.10.007_bb0260","first-page":"30063","article-title":"Analysis of SOST expression using large minigenes reveals the MEF2C binding site in the evolutionarily conserved region (ECR5) enhancer mediates forskolin, but not 1,25-dihydroxyvitamin D or TGFbeta responsiveness","author":"St John","year":"2015","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0265","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1172\/JCI40568","article-title":"Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice","volume":"120","author":"Walker","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"13\u201314","key":"10.1016\/j.bone.2016.10.007_bb0270","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1089\/ten.tea.2014.0585","article-title":"Estrogen modulates bone morphogenetic protein-induced sclerostin expression through the Wnt signaling pathway","volume":"21","author":"Kim","year":"2015","journal-title":"Tissue Eng. Part A"},{"issue":"12","key":"10.1016\/j.bone.2016.10.007_bb0275","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1210\/en.2015-1244","article-title":"Regulation of sclerostin production in human male osteocytes by androgens: experimental and clinical evidence","volume":"156","author":"Di","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2016.10.007_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2869","article-title":"Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost\/sclerostin","author":"Sato","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.10.007_bb0285","first-page":"30152","article-title":"Early response of the human SOST gene to stimulation by 1alpha,25-dihydroxyvitamin D","author":"Wijenayaka","year":"2015","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"12","key":"10.1016\/j.bone.2016.10.007_bb0290","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/jbmr.1718","article-title":"High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study","volume":"27","author":"Ardawi","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2016.10.007_bb0295","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/EJE-13-0862","article-title":"Effect of supplemental vitamin D and calcium on serum sclerostin levels","volume":"170","author":"Dawson-Hughes","year":"2014","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"10.1016\/j.bone.2016.10.007_bb0300","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00296-015-3294-1","article-title":"Serum sclerostin is decreased following vitamin D treatment in young vitamin D-deficient female adults","volume":"35","author":"Cidem","year":"2015","journal-title":"Rheumatol. Int."},{"issue":"4","key":"10.1016\/j.bone.2016.10.007_bb0305","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1515\/jpem-2015-0222","article-title":"Low serum sclerostin levels in newborns with vitamin D deficiency","volume":"29","author":"Pirgon","year":"2016","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.10.007_bb0310","article-title":"Effect of vitamin D treatment on serum sclerostin level","author":"Acibucu","year":"2016","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"8","key":"10.1016\/j.bone.2016.10.007_bb0315","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1359\/jbmr.090305","article-title":"Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts","volume":"24","author":"Vincent","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0320","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bbrc.2015.02.091","article-title":"Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells","volume":"461","author":"Tanaka","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2016.10.007_bb0325","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.3007","article-title":"PTHrP-derived peptides restore bone mass and strength in diabetic mice: additive effect of mechanical loading","author":"Maycas","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2016.10.007_bb0330","first-page":"355","article-title":"Dissecting the hematopoietic microenvironment. VIII. Clonal isolation and identification of cell types in murine CFU-F colonies by limiting dilution","volume":"18","author":"Wang","year":"1990","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bone.2016.10.007_bb0335","first-page":"19","article-title":"Measurement of caspase activity in cells undergoing apoptosis","volume":"282","author":"Kumar","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bone.2016.10.007_bb0340","series-title":"Human Tumor Cells in Vitro","first-page":"115","article-title":"New human tumor cell lines","author":"Fogh","year":"1975"},{"key":"10.1016\/j.bone.2016.10.007_bb0345","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1210\/endo.134.2.8299560","article-title":"17b-Estradiol and parathyroid hormone potentiate each other's stimulatory effects on alkaline phosphatase activity in SaOS-2 cells in a differentiation-dependent manner","volume":"134","author":"Rao","year":"1994","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.bone.2016.10.007_bb0350","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1359\/jbmr.2001.16.9.1622","article-title":"Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture","volume":"16","author":"Kato","year":"2001","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2016.10.007_bb0355","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1359\/jbmr.1997.12.12.2014","article-title":"Establishment of an osteocyte-like cell line, MLO-Y4","volume":"12","author":"Kato","year":"1997","journal-title":"J. Bone Miner. Res."},{"issue":"27","key":"10.1016\/j.bone.2016.10.007_bb0360","doi-asserted-by":"crossref","first-page":"16744","DOI":"10.1074\/jbc.M114.628313","article-title":"The Wnt-inhibitor sclerostin is up-regulated by mechanical unloading in osteocytes in-vitro","volume":"290","author":"Spatz","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.10.007_bb0365","doi-asserted-by":"crossref","DOI":"10.1007\/s00774-016-0753-z","article-title":"Generation and characterization of two immortalized human osteoblastic cell lines useful for epigenetic studies","author":"Perez-Campo","year":"2016","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2016.10.007_bb0370","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bone.2016.01.024","article-title":"Successful induction of sclerostin in human-derived fibroblasts by 4 transcription factors and its regulation by parathyroid hormone, hypoxia, and prostaglandin E2","volume":"85","author":"Fujiwara","year":"2016","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2016.10.007_bb0375","doi-asserted-by":"crossref","first-page":"E478","DOI":"10.1073\/pnas.1409857112","article-title":"Osteocytes mediate the anabolic actions of canonical Wnt\/b-catenin signaling in bone","volume":"112","author":"Tu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.bone.2016.10.007_bb0380","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1210\/en.2014-1046","article-title":"Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes","volume":"155","author":"Ben-Awadh","year":"2014","journal-title":"Endocrinology"},{"issue":"23","key":"10.1016\/j.bone.2016.10.007_bb0385","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.bone.2016.10.007_bb0390","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.bone.2016.10.007_bb0395","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.bbrc.2014.03.079","article-title":"New insights into the location and form of sclerostin","volume":"446","author":"Hernandez","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bone.2016.10.007_bb0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2013.10.019","article-title":"Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans","volume":"59","author":"Roforth","year":"2014","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0405","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.217","article-title":"Relation of age, gender, and bone mass to circulating sclerostin levels in women and men","volume":"26","author":"Modder","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2016.10.007_bb0410","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2011-2152","article-title":"Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults","volume":"97","author":"Amrein","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.10.007_bb0415","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/bonekey.2013.95","article-title":"Clinical utility of serum sclerostin measurements","volume":"2","author":"Clarke","year":"2013","journal-title":"Bonekey Rep."},{"issue":"11","key":"10.1016\/j.bone.2016.10.007_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007930","article-title":"Lrp4, a novel receptor for dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo","volume":"4","author":"Choi","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bone.2016.10.007_bb0425","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bbrc.2016.01.178","article-title":"The systemic effects of sclerostin overexpression using PhiC31 integrase in mice","volume":"472","author":"Zhang","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.bone.2016.10.007_bb0430","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/jnnp.45.10.913","article-title":"Two cases of Van Buchem's disease","volume":"45","author":"Dixon","year":"1982","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.bone.2016.10.007_bb0435","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/jbmr.2259","article-title":"Sclerostin deficiency is linked to altered bone composition","volume":"29","author":"Hassler","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0440","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","article-title":"Functions of RANKL\/RANK\/OPG in bone modeling and remodeling","volume":"473","author":"Boyce","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"issue":"5","key":"10.1016\/j.bone.2016.10.007_bb0445","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev. Cell"},{"issue":"22","key":"10.1016\/j.bone.2016.10.007_bb0450","doi-asserted-by":"crossref","first-page":"21162","DOI":"10.1074\/jbc.M501900200","article-title":"Essential role of beta-catenin in postnatal bone acquisition","volume":"280","author":"Holmen","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bone.2016.10.007_bb0455","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1128\/MCB.01428-09","article-title":"Osteocyte Wnt\/beta-catenin signaling is required for normal bone homeostasis","volume":"30","author":"Kramer","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bone.2016.10.007_bb0460","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bone.2014.07.031","article-title":"Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats","volume":"67","author":"Stolina","year":"2014","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.bone.2016.10.007_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025900","article-title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway","volume":"6","author":"Wijenayaka","year":"2011","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.bone.2016.10.007_bb0470","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1128\/MCB.05980-11","article-title":"Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin","volume":"31","author":"Wei","year":"2011","journal-title":"Mol. Cell. Biol."},{"issue":"26","key":"10.1016\/j.bone.2016.10.007_bb0475","doi-asserted-by":"crossref","first-page":"24113","DOI":"10.1074\/jbc.M301716200","article-title":"Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity","volume":"278","author":"Kusu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.10.007_bb0480","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2782","article-title":"A novel domain-specific mutation in a sclerosteosis patient suggests a role of LRP4 as an anchor for sclerostin in human bone","author":"Fijalkowski","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0485","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.bbrc.2011.12.048","article-title":"The sclerostin-bone protein interactome","volume":"417","author":"Devarajan-Ketha","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.bone.2016.10.007_bb0490","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/jbmr.1608","article-title":"Absence of sclerostin adversely affects B-cell survival","volume":"27","author":"Cain","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2016.10.007_bb0495","first-page":"317","article-title":"Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study","volume":"22","author":"Koos","year":"2013","journal-title":"J. Heart Valve Dis."},{"issue":"3","key":"10.1016\/j.bone.2016.10.007_bb0500","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jbmr.2372","article-title":"Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy","volume":"30","author":"Moe","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2016.10.007_bb0505","doi-asserted-by":"crossref","first-page":"E1473","DOI":"10.1210\/jc.2012-1218","article-title":"Association of circulating sclerostin levels with fat mass and metabolic disease-related markers in Japanese postmenopausal women","volume":"97","author":"Urano","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.10.007_bb0510","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/261545","article-title":"Circulating sclerostin and irisin are related and interact with gender to influence adiposity in adults with prediabetes","volume":"2014","author":"Klangjareonchai","year":"2014","journal-title":"Int. J. Endocrinol."},{"issue":"6","key":"10.1016\/j.bone.2016.10.007_bb0515","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/jcb.25432","article-title":"Sclerostin enhances adipocyte differentiation in 3T3-L1 cells","volume":"117","author":"Ukita","year":"2016","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.bone.2016.10.007_bb0520","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jcb.240550304","article-title":"Function of osteocytes in bone","volume":"55","author":"Aarden","year":"1994","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0525","first-page":"73","article-title":"The mechanostat: a proposed pathogenic mechanism of osteoporoses and the bone mass effects of mechanical and nonmechanical agents","volume":"2","author":"Frost","year":"1987","journal-title":"Bone Miner."},{"issue":"9","key":"10.1016\/j.bone.2016.10.007_bb0530","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bone.2016.10.007_bb0535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002942","article-title":"Control of bone mass and remodeling by PTH receptor signaling in osteocytes","volume":"3","author":"O'Brien","year":"2008","journal-title":"PLoS One"},{"issue":"41","key":"10.1016\/j.bone.2016.10.007_bb0540","doi-asserted-by":"crossref","first-page":"31720","DOI":"10.1074\/jbc.M602308200","article-title":"WNT\/beta-catenin signaling is a normal physiological response to mechanical loading in bone","volume":"281","author":"Robinson","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"28","key":"10.1016\/j.bone.2016.10.007_bb0545","doi-asserted-by":"crossref","first-page":"20122","DOI":"10.1074\/jbc.M112.441360","article-title":"Parathyroid hormone (PTH)\/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH","volume":"288","author":"Saini","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.10.007_bb0550","article-title":"Control of bone anabolism in response to mechanical loading and PTH by distinct mechanisms downstream of the PTH receptor","volume":"2016","author":"Delgado-Calle","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"41","key":"10.1016\/j.bone.2016.10.007_bb0555","doi-asserted-by":"crossref","first-page":"29809","DOI":"10.1074\/jbc.M113.485938","article-title":"Resorption controls bone anabolism driven by PTH receptor signaling in osteocytes","volume":"288","author":"Rhee","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bone.2016.10.007_bb0565","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1210\/en.2011-0049","article-title":"Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice","volume":"152","author":"Robling","year":"2011","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.bone.2016.10.007_bb0570","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/01.med.0000436249.84273.7b","article-title":"Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoids","volume":"20","author":"Warriner","year":"2013","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"1","key":"10.1016\/j.bone.2016.10.007_bb0575","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","article-title":"Clinical practice. Glucocorticoid-induced bone disease","volume":"365","author":"Weinstein","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bone.2016.10.007_bb0580","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1002\/art.30385","article-title":"Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone","volume":"63","author":"Marenzana","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.bone.2016.10.007_bb0585","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00198-015-3308-6","article-title":"Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength","volume":"27","author":"Yao","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"12","key":"10.1016\/j.bone.2016.10.007_bb0590","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/jbmr.151","article-title":"Glucocorticoids are not always deleterious for bone","volume":"25","author":"van Lierop","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.10.007_bb0595","doi-asserted-by":"crossref","first-page":"11505","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bone.2016.10.007_bb0600","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2016.10.007_bb0605","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2016.10.007_bb0610","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0615","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/leu.2013.258","article-title":"Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma","volume":"28","author":"Greenberg","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bone.2016.10.007_bb0620","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.bone.2016.10.007_bb0625","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2016.10.007_bb0630","series-title":"38th Annual Meeting of the American Society for Bone and Mineral Research. Atlanta, GA, USA","article-title":"Genetic sost deletion or pharmacological inhibition of sclerostin prevents bone loss and decreases osteolytic lesions in immunodeficient and immunocompetent","author":"Delgado-Calle","year":"2016"},{"issue":"23","key":"10.1016\/j.bone.2016.10.007_bb0635","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1182\/blood.V126.23.119.119","article-title":"Anti-sclerostin treatment prevents multiple myeloma induced bone loss and reduces tumor burden","volume":"126","author":"Reagan","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0640","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00198-013-2462-y","article-title":"Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids","volume":"25","author":"Garcia-Fontana","year":"2014","journal-title":"Osteoporos. Int."},{"issue":"5","key":"10.1016\/j.bone.2016.10.007_bb0645","doi-asserted-by":"crossref","first-page":"R106","DOI":"10.1186\/bcr3048","article-title":"Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2\/CBFbeta-dependent expression of the Wnt antagonist, sclerostin","volume":"13","author":"Mendoza-Villanueva","year":"2011","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.bone.2016.10.007_bb0650","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00223-016-0126-6","article-title":"Sclerostin inhibition in the management of osteoporosis","volume":"98","author":"Appelman-Dijkstra","year":"2016","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"10.1016\/j.bone.2016.10.007_bb0655","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bone.2016.10.007_bb0660","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.bone.2016.10.007_bb0665","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.2489","article-title":"The effect of discontinuing treatment with Blosozumab: follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density","volume":"30","author":"Recknor","year":"2015","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216302976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216302976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T13:05:07Z","timestamp":1657458307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328216302976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":132,"alternative-id":["S8756328216302976"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.10.007","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role and mechanism of action of sclerostin in bone","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}